Simeon George, CEO and managing partner for SR One, about the firm’s investment approach, how the current landscape is causing venture capitalists and therapeutics developers to think differently, and what advice he’d offer entrepreneurs seeking to raise money today.

A Venture Capitalist’s View of the Current Biotech Landscape

The Bio Report podcast, hosted by award-winning journalist Daniel Levine, focuses on the intersection of biotechnology with business, science, and policy.

Business

Investing

Careers

Management & Marketing

Business News

Shopping

Science

Life Sciences

Bobby Azamian, CEO of Tarsus, discusses Lyme disease, the case for the company’s experimental prophylactic drug TP-05, and why you may already have been using a form of the drug to protect a four-legged member of your household.

Teaching an Old Drug a New Trick to Prevent Lyme Disease

Jason Bock, CEO of CMTC, the joint venture between Resilience and MD Anderson Cancer Center, discusses the emerging area of TIL therapies, the significance of the first approved therapy in the class, and how they may address existing limitations of CAR-T therapies.

A New Class of Cell Therapies to Target Solid Tumors

Don Wyatt, chief business officer for Highfield Biopharmaceuticals, discusses the tumor microenvironment, HighField’s platform technology, and how it is developing lipid-based medicines to overcome challenges of existing immunotherapies.

Targeting the Tumor Microenvironment with Lipid-Based Immunotherapies

Jeremiah Robison, CEO of Cionic, discusses the company’s Neural sleeve, how functional electronical stimulation helps people with movement disorders walk, and how the use of adaptive algorithms continuously optimizes the stimulation it delivers.

A Company Born from a Father Who Wore His Heart on His Sleeve

Pete Carlson, CEO of Spectral AI, discusses the company’s AI-driven DeepView System for assessing burns, how it provides clinicians an objective and immediate assessment of a wound’s healing potential, and how it changes outcomes for patients.

A Venture Capitalist’s View of the Current Biotech Landscape

Download our free app to listen on your phone